



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

Impurity profiling of pharmaceutical Formulation

Rajnanda Patil*, Srushti Aoundhkar, Priyanka Mohite, Dr. D. R. Jadge

Womens College Of Pharmacy Peth Vadgoan.

ARTICLE INFO

Published: 27 May 2025

Keywords:

Impurities, pharmaceutical products, impurity profiling, regulatory authorities, analytical techniques

DOI:

10.5281/zenodo.15524774

ABSTRACT

Impurity profiling is an essential tool for the pharmaceutical business, and this article delves into that role extensively. Drug safety and effectiveness might be jeopardized when active pharmaceutical ingredients (APIs) are mixed with impurities, which are undesirable chemical compounds. To guarantee the detection and control of contaminants in both APIs and formulated goods, numerous regulatory agencies have set rigorous purity standards, such as ICH, FDA, and CDHA. Particular emphasis is placed on the limits that can be tolerated for organic, inorganic, and residual solvent contaminants. The concept of impurity profiling is described, including its use in medication design, quality assurance, and safety evaluation. It includes steps such as quantitative determination, structural elucidation, and identification. Hyphenated processes such as liquid chromatography-mass spectrometry and liquid chromatography-nuclear spectrometry are addressed in the article, along with accelerated solvent extraction, gas chromatography, nuclear magnetic resonance, mass spectrometry, and more. To ensure the efficacy and safety of pharmaceutical goods, impurity profiling plays a crucial role, as this comprehensive review shows

INTRODUCTION

Impurity:

During production or storage, impurities can form in drug substances or drug products, and they are compounds that are neither wanted nor intended to be in APIs. Those things lower the substances or product's quality, safety, and effectiveness without necessarily rendering it useless for its original

reason. "Impurities are undesirable chemicals (or) substance present in therapeutic products," stated the International Conference on Harmonization (ICH) in its guidelines. This has no effect on the body's chemicals

Impurity profiling:

This set of analytical procedures is known as impurity profiling. It refers to process of finding

***Corresponding Author:** Rajnanda Patil

Address: Womens College of Pharmacy Peth Vadgoan.

Email ✉: rajnandapatil3003@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



and quantifying organic and inorganic contaminants, residual solvents, and other contaminants in pharmaceutical and bulk drug formulations. (Instead of) Impurity profiling is the process of describing, characterising, and quantifying the identified and unidentified impurities found in novel medicinal compounds.

Introduction

One of the pharmacological effects is produced by the active pharmaceutical ingredients (API), which are part of the therapeutically active product together with excipients. [1]. In addition to the API and excipients, impurities can be defined as any other substances that are not intended for human consumption. Anything organic or undesired that stays with active pharmaceutical ingredients (APIs) is considered an impurity in the pharmaceutical business. It is possible for contaminants to arise in both APIs and formulations at any stage of production. Medicinal medications may lose some of their efficacy or become unsafe if these undesirable substances are added. Anything organic or undesired that stays with active pharmaceutical ingredients (APIs) is considered an impurity in the pharmaceutical business. It is possible for contaminants to arise in both APIs and formulations at any stage of production.

Regulatory guidelines for impurities in API

The subsequent are different regulatory necessities of ICH

1. Evaluation of New Pharmaceutical Substances and Their Stability.

2. Contaminants in Emerging Medicinal Substances Separate from impurity control is the process of monitoring. Consequently, it is important to use simple language when responding to questions regarding pollutants. Separate from impurity control is the process of monitoring. Consequently, it is important to use simple language when responding to questions regarding pollutants.
3. Impurities: Residual Solvent is the fourth recommendation.
4. Impurities in New Drugs.
5. ANDA Contaminants in Novel Medicinal Substances
6. The USFDA Standards for Contaminants in New Medicinal Substances NDAs.
7. Treatment Australia's Australian Prescription Drug Regulatory Guide (TG0) [2]


Sources Of Impurities

To name just a few examples, enantiomeric impurities; heavy metals; ligands; catalysts; filter aids; charcoal; degraded byproducts of hydrolysis, photolytic cleavage, oxidative degradation, decarboxylation, and other processes; and so on are all potential sources of impurities in pharmaceutical products. Some possible sources of contamination in medicinal medications include the following.

1. The starting ingredients.
2. The production process used
3. Because the product is not stable.
4. from pollutants in the air.
5. Impurities (such as polymorphism) associated with crystallisation [3]

Classification of Impurity [4-8]





Organic impurities:

If the multistep synthesis process is not carried out with sufficient care, these contaminants will be present in every API. They could be recognised or remain anonymous. You can find them in volatile or non-volatile forms. It might be one of these things.

- a) Primary Ingredients
- b) Final Product
- c) Transfer Steps
- d) Chemical Agents

Inorganic impurities:

They might also originate in the procedures used to make bulk medications. Common examples of these include heavy metals, catalysts, reagents, ligands, charcoals, and filter aids. In order to identify and measure inorganic pollutants, it is common practice to refer to pharmacopoeia or other applicable standards. It is important to evaluate the transferability of catalysts to the medicinal ingredient throughout development.

Residual solvents:

Organic volatile compounds utilised or produced as a byproduct of manufacturing processes are

known as residual solvents. The medication production procedure should not involve the use of certain solvents due to their known toxicity. In terms of the danger they could cause to humans, residual solvents fall into one of three types:

Category1: includes substances that can cause cancer in humans.

Category 2: Safe for gene expression. Third category: less danger to people's health [9,10]

Need for Impurity profiling:

Examination of impurities in raw materials used for formulation is an essential part of any formulation's production process. These impurities may alter the solubility of APIs. Api safety and efficacy are jeopardised when these unwanted chemicals are present since they can affect a medicine's safety characteristics through inducing toxicities in the body or undesirable drug reactions.[11]

Formulation Related Impurities

One source of drug product contaminants is the use of inactive substances in drug formulation. A drug material is vulnerable to deterioration and other harmful reactions during formulation due to the



wide range of environments it must endure. Hydrolysis has the potential to degrade suspensions and solutions. The water used in the formulation might not only introduce new pollutants, but it might also provide the perfect conditions for hydrolysis and catalysis. There are other solvents that could cause similar effects. Here are the several types of contaminants that are associated with the formulation: [12-13]

- Approach connected
- Environmentally concerned

The main elements of the surrounding environment that have the potential to decrease stability are the following:

I. Dangers posed by extreme weather conditions

II. light, and more specifically ultraviolet light

Chap. III. Humidity

Dosage form related

- The interplay between components
- The usual breakdown associated with functional groups
- Hydrolysis of esters
- The process of hydrolysis
- Chemical deterioration
- Hydrolysis by light
- Chemical oxidation

Method linked It is still possible to develop the recognised contaminant 1-(2, 6-dichlorophenyl) indolin-2-one while making a parenteral dosage form of diclofenac sodium, even after autoclaving it. Under the autoclave method's conditions (i.e., $123 \pm 2^\circ\text{C}$), diclofenac sodium underwent an intramolecular cyclic reaction to produce sodium hydroxide and the indolinone derivative. This pollutant develops in response to changes in the beginning pH of the formulation, according to the

research. The finished ampoule has a greater impurity level than the BP limit of the raw material. Environmentally conscious. Several typical environmental factors can reduce stability, including: Exposure to very high or low temperatures: Tropical conditions are particularly harsh for several active pharmacological components because of their heat sensitivity. For instance, vitamins are very heat-sensitive as medical substances, and their efficiency might be diminished, especially in liquid form, due to deterioration. heat, and specifically, UV light: Many field samples had incredibly low concentrations of the active component, and investigations have demonstrated that ergometrine and methyl ergometrine injection are unstable in tropical regions, particularly when exposed to light and heat. Almost half of the ergometrine injections tested did not contain enough of the active ingredient to be considered meeting the BP/USP criteria of 90% to 110%. The ergometrine injection (0.2 mg/mL) showed almost complete degradation after 42 hours of sun exposure. Dew point: Hygroscopic goods are believed to be hydrophobic in both their bulk powder and prepared solid dosage forms. Among the classics are medications like aspirin and ranitidine. Other means of dosing Stability tests and other preformulation research are conducted by pharmaceutical businesses prior to the public release of their goods. On the other hand, problems with dosage forms affecting drug stability do occur, and in such cases, the corporation is compelled to recall the product. Oral liquid goods meant for human consumption are at risk of contamination from an overabundance of bacteria, fungi, and yeast in a warm and humid environment. Microbiological contaminants may develop in a multiple-dose product over time as a result of the semi-permeable structure of the main containers or the incorrect use of certain preservatives in the preparations.



Analytical Techniques for Impurity Profiling

Forensic science relies heavily on impurity profiling, especially when working with pollutants or trace evidence. The analytical methods employed determine the precision and dependability of impurity profiling. Significance of comprehensive impurity profiling is increasing as the complexity of drug products rises, prompting developments in analytical methods and regulatory science. Chromatographic methods, spectroscopic approaches, and the hyphenated methodology are the three primary categories under which impurity profiling falls.

Thin Layer Chromatography (TLC):

It is a method for separating and identifying compounds by measuring their affinity to two phases: stationary phase and mobile phase. It has a large sample loading capacity, requires little in the way of sample clean-up, and offers a variety of mobile phases to choose from. The area of pharmaceutical analysis makes extensive use of this affordable and ancient method. A solid support, such as glass, plastic, or aluminium, is thinly covered with the adsorbent, which is in a solid state. The success of this chromatographic separation method depends on a number of things. When data regarding the drug's impurities and degradation products is lacking in the early stages of research, TLC is vital [14,15]. Aspirin and other pharmaceuticals can undergo preliminary screening for contaminants using TLC. It provides a quick and cheap way to separate degradation products, which is particularly useful for stability testing. [16].

High Performance Thin Layer Chromatography (HPTLC):

Modern methods have made HPTLC an indispensable instrument for the examination of

pharmaceuticals. Rapid and adaptable, HPTLC permits for analysis of a diverse array of samples. This approach is great for evaluating complicated or raw sample preparations because of its many benefits, such as its simplicity and quick analysis timeframes. There are no time limits when using HPTLC to analyse the full chromatogram using different settings. The results are even more reliable because it enables numerous samples and standards to be developed independently on each plate at the same time. The following medications have been quantified using HPTLC: ethinylestradiol, cyproterone, alfuzosin, pentazocine, and tramadol [17], [18], and [19]. Because it can process numerous samples at once, the method is perfect for screening drugs on a massive scale.

Gas Chromatography (GC):

To ensure that drugs are safe, effective, and compliant with regulations, GC is an essential tool for detecting and characterising volatile and semi-volatile contaminants in pharmaceuticals. Good candidates for GC include volatile chemical molecules, environmental contaminants, and pharmaceutical impurities since the technique separates analytes according to their boiling temperatures and interactions with a stationary phase. In the synthesis of Active Pharmaceutical Ingredients (APIs), organic solvents like ethanol and methanol are commonly used for a variety of purposes, such as reaction media, purification, yield enhancement, and crystallisation control. One common use is the quantification of these residual solvents. The method can reliably measure complex mixtures, even those containing trace-level chemicals, to within a few parts per trillion, thanks to its great sensitivity and separation efficiency. Derivatisation may be necessary for high-molecular-weight molecules such polypeptides or thermally unstable antibiotics



since they are non-volatile, despite the fact that GC is quite successful for volatile and semi-volatile chemicals. Isotretinoin, cocaine, and betamethasone valerate assays are only a few examples of the many pharmaceutical analyses that make use of GC, despite its limitations. Other applications include process control, residual solvent detection, and batch consistency verification. Using a variety of detectors, it is also useful for finding process-related contaminants, which is essential for meeting standards set by organizations like the International Conference on Harmonization. [20,21,22]

Liquid Chromatography-Mass Spectrometry (LC-MS):

One common analytical tool for characterizing medication contaminants is LC-MS. Impurities in pharmaceuticals can be identified and quantified with the use of LC-MS, a technology that combines the separation power of LC with the detection capabilities of MS. The mass spectrometer identifies molecules by analysing their mass-to-charge ratio, while the liquid chromatography part effectively separates contaminants according to properties like solubility and polarity [23]. This setup makes LC-MS perfect for tracking down degradation products, residual solvents, and other pollutants that could jeopardise the efficacy and safety of drugs, since it can identify these substances at incredibly low concentrations. In addition, LC-MS can help comprehend the effect of unknown contaminants on drug stability and performance by revealing their molecular structure. Stability studies, method development, and meeting high quality standards are all steps in the pharmaceutical process that rely on this technology. When it comes to biologic medications, such as monoclonal antibodies, it is very successful in detecting trace degradation

products and in finding Post-Translational Modifications (PTMs) that could affect therapeutic efficacy [24]. Because of its great sensitivity, specificity, and adaptability, LC-MS is useful for analysing medication impurities. By giving precise information regarding the kind, amount, and structure of contaminants, it is crucial for pharmaceutical goods to be safe, effective, and compliant with regulations.

UV-Visible Spectroscopy:

When it comes to finding and measuring drug contaminants, ultraviolet-visible spectroscopy is an indispensable instrument for the pharmaceutical sector. It is perfect for regular quality control and medication purity monitoring because it is simple, inexpensive, and accurate. This method gives useful information on the chemical make-up and amount of contaminants in a medicinal substance by assessing the sample's absorbance or transmission of ultraviolet (UV) or visible (VIS) light. The precise wavelengths at which various contaminants absorb light allow for their identification through their unique absorption spectra. We can measure the concentration of these contaminants by taking absorbance readings at specific wavelengths, comparing them to known standards, or utilising calibration curves. Since it may identify any discrepancies from the anticipated absorption profile, ultraviolet-visible spectroscopy is especially useful for ensuring the quality and purity of drugs during production and quality control. In addition, as medications undergo degradation, they produce contaminants. By monitoring changes in the absorption spectra or the appearance of new peaks, UV-Visible spectroscopy can spot these degradation products. [25].

CONCLUSION:



A pharmaceutical ingredient must satisfy the requirements for a novel impurity in addition to passing the CGMP, QC, QA, and water activity tests. Information regarding the impurities found in pharmaceutical compounds and products is given in this article. It provides impurity ICH limits. The analytical impurity profiling are also covered in this article. The primary goal of impurity profiling is to identify any new entities that exceed the threshold limit of Pharmaceutical components must meet the designated threshold in addition to passing CGMP, quality control, quality assurance, and water activity testing. Finding the novel substance in pharmaceutical formulations over its threshold limit of 0.1% is the primary goal of impurity profiling. As a result, the analyst who is doing the quantification must use the appropriate techniques.

REFERENCES

1. Ramachandra, B. (2017). Development of impurity profiling methods using modern analytical techniques. Critical reviews in analytical chemistry, 47(1), 24-36.
2. Bhagwat Ashlesha, B., & Khedkar, K. M. (2022). Impurity Profiling: A Review. Asian J. Pharm. Res. Develop, 10, 135-143.
3. Chandra, M. Dr. Bhimrao Ambedkar and his idea of State Socialism. Contributions and Relevance of BR Ambedkar's Thoughts in Contemporary India.
4. Roy, J., Islam, M., Khan, A. H., Das, S. C., Akhteruzzaman, M., Deb, A. K., Alam, A. H. M., J Pharm Sci. 2001, 90, 541-544.
5. Walker, G. J. A., Hogerzeil, H. V., Hillgreen, U., Lancet. 1988, 2, 393.
6. Hogerzeil, H. V., Battersby, A., Srdanovic, V., Stjernstrom, N. E., British Medical J. 1992, 304, 210-214.
7. Food and Drug Administration for immediate release consumer media: 888-Info-FDA. May 6, 1998.
8. Hoq, M. M., Morsheda, S. B., Gomes, D. J., Bang J. Microbiology. 1991, 8(1), 5-9.
9. Gupta Raghav, Dr. Jain Suresh, Gupta Ankit, A Review on Impurity Profile of Pharmaceuticals, International Journal of Drug Formulation and Research 2014; 5:60-61.
10. Bari S. B., Jain P.S., Shirkhedkar A.A., Sonawane L.V., Mhaske A.J., Gawad J.B., Impurities in Pharmaceutical: A Review, World Journal of Pharmaceutical Research 2015; 4:2936-2937.
11. Venkatesan P., and Valliappan K. , Impurity Profiling: Theory and Practice , Department of Pharmacy, Faculty of Engineering and Technology, Annamalai University, Annamalai nagar, (2014) :254-269
12. Radhakrishna T, Satynarayana J and Satynarayana A (2002) Determination of Loratidine and its Related Impurities by HPLC. Indian Drugs 39 (6): 342.
13. Radhakrishna T, Satynarayana J and Satynarayana A (2002) HPLC method for the Degradation of Celecoxib and its Related Impurities. Indian Drugs 40(3): 166.
14. White D, Varlashkin P, Rusch DN (1992) Detection of Impurities: A Review on Advance in Impurities Detection and Characterization in Pharmaceuticals by Analytical Techniques. J Pharm Sci 81: 1204-1209
15. S. Ahuja, S. Scypinski. Handbook of Modern Pharmaceutical Analysis, Vol. 3, Separation Science and Technology, Academic press, 2003
16. J. Roy. Pharmaceutical Impurities—a mini review, AAPS PharmSciTech 3(2): 1-8 (2002). ICH Harmonized Triplicate Guideline: Impurities in New Drug Substances Q3A (R2), ICH Steering Committee, Step 4 of ICH process, 25th Oct. 2006
17. Pavic K, Cudina O, Agbaba D, Vladimirov S (2003) Quantitative analysis of cyproterone acetate and ethinylestradiol in tablets by use of



planar chromatography. J Planar Chromatogr Mod TLC 16(1): 45-47.

diode array spectral matching. J Pharm Biomed Anal 16(5): 813-824.

18. Fayed AS, Shehata MAA, Hassan NY, El-Weshahy SA (2006) Validated HPLC and HPTLC stability-indicating methods for determination of alfuzosin hydrochloride in bulk powder and pharmaceutical formulations. J Sep Sci 29(18): 2716-2724
19. Desai P, Captain A, Kamdar S (2012) Development and Validation of HPTLC Method for Estimation of Tramadol HCl in Bulk and in Capsule Dosage Form. Int J Pharm Tech Res 4(3): 1261-1265,
20. Reddy BP, Reddy MS (2009) Residual solvents determination by HS-GC with Flame Ionization Detector in Omeprazole Pharmaceutical formulations. Int Pharm Tech Res 1(2): 230-234.
21. Hashimoto K, Urakami K, Fujiwara Y, Terada S, Watanabe C (2001) Determination of Residual Solvents in Pharmaceuticals by Thermal Desorption-GC/MS. Anal Sci 17(5): 645-648.
22. Saraji M, Khayamian T, Siahpoosh ZH, Farajmand B (2012) Determination of volatile residual solvents in pharmaceutical products by static and dynamic headspace liquid-phase microextraction combined with gas chromatography-flame ionization detection. Anal Methods (6): 1552-1559
23. Ermer J (1998) The use of hyphenated LC–MS technique for characterisation of impurity profiles during drug development. J Pharm Biomed Anal 18(4-5): 707-714.
24. Peng W, Pronker MF, Snijder J (2021) Mass spectrometry based De Novo sequencing of monoclonal antibiotics using multiple proteases and a dual fragmentation scheme. J Proteome Res 20(7): 3559-3566
25. Nicolas EC, and Scholz TH (1998) Active drug substance impurity profiling: Part I. LC/UV

HOW TO CITE: Rajnanda Patil*, Srushti Aoundhkar, Priyanka Mohite, Dr. D. R. Jadge, Impurity profiling of pharmaceutical Formulation, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 5, 4520-4527. <https://doi.org/10.5281/zenodo.15524774>

